Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1

This publication has 15 references indexed in Scilit:

• Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
  Haematologica, 2014
• The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
  Blood, 2013
• Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments
  Journal of Computer-Aided Molecular Design, 2013
• Pushing the limits of targeted therapy in chronic myeloid leukaemia
  Nature Reviews Cancer, 2012
• Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
  Blood, 2011
• Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
  New England Journal of Medicine, 2010
• Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
  New England Journal of Medicine, 2006
• Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
  Cancer Cell, 2005
• BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90
  Blood, 2002
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
  Cancer Cell, 2002